Search clinical trials for: Neoadjuvant Nivolumab

Total 2335 results

Eye & ENT Hospital of Fudan University
Peking University Third Hospital; Zhongshan Ophthalmic Center, Sun Yat-sen... and other collaborators

Recruiting

Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors

Malignant Tumor of Lacrimal Drainage Structure

China
Seoul National University Hospital

Completed

Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

Breast Cancer

Korea, Republic of
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Terminated

A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer

Cervical Neoplasms

Japan
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
University of Pittsburgh
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

United States
University Hospital, Rouen
Federation Francophone de Cancerologie Digestive; UNICANCER; Federation of Research... and other collaborators

Unknown

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01)

Resectable Pancreatic Duct Adenocarcinoma

France
Hospital del Mar

Not yet recruiting

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline (PaNLoCat)

Chemotherapy Effect | Pancreas Cancer

Spain
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
University of California, San Francisco
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

HIV/AIDS | Kaposi Sarcoma | Immunosuppression

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
University Hospital, Lille
Ministry of Health, France

Recruiting

Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study. (KARCHER-1)

Hepatocellular Carcinoma

France
CHIR-Net
Technical University of Munich

Terminated

Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (Net-Pac)

Pancreatic Adenocarcinoma

Germany
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Case Comprehensive Cancer Center

Withdrawn

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer
European Association for Endoscopic Surgery

Completed

Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer (NERATEM)

RECTAL CANCER

Italy
Haukeland University Hospital
Pfizer; AstraZeneca; Helse Vest

Active, not recruiting

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC)

Breast Cancer

Norway
Medical College of Wisconsin

Terminated

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Chronic Leukemia

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Tianjin Medical University Cancer Institute and...

Unknown

Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Unresectable Esophageal Cancer

China
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Shanghai Zhongshan Hospital
Shenzhen University General Hospital; Xuhui Central Hospital, Shanghai; Minhang... and other collaborators

Recruiting

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Cholangiocarcinoma, Intrahepatic

China
Zhejiang Cancer Hospital

Completed

Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer

Breast Cancer | HER2 | Preoperative Systemic Treatment
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma

Hilar Cholangiocarcinoma

China
Zhejiang University

Recruiting

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 (TACTIC)

Locally Advanced Gastric Carcinoma

China
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Netherlands, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico
University of Chicago

Recruiting

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Metastatic Cancer

United States
Kyowa Kirin, Inc.
Bristol-Myers Squibb

Completed

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Carcinoma | HCC | Cancer | Hepatocellular Carcinoma | Solid Tumor

United States
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
Mansoura University

Recruiting

Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy

Breast Cancer

Egypt
Ankara Etlik City Hospital

Completed

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Bladder Cancer | Bladder Cancer Stage I | Bladder Cancer Stage II

Turkey
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Intrahepatic Cholangiocarcinoma Recurrent
Zagazig University

Completed

Role of Laparoscopy in Assessing Resectability of Ovarian Cancer

Ovarian Cancer

Egypt
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Breast Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Hospital Vall d'Hebron

Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Unresectable Cholangiocarcinoma

Spain
Dana-Farber Cancer Institute

Completed

Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy

Breast Cancer

United States
German Cancer Research Center
University Hospital Heidelberg

Active, not recruiting

Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (BENEFIT)

Breast Cancer

Germany
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
HUYABIO International, LLC.

Completed

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

United States
The Clatterbridge Cancer Centre NHS Foundation...
Bristol-Myers Squibb; University of Liverpool

Active, not recruiting

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer (NICO)

Squamous Cell Carcinoma of the Oral Cavity

United Kingdom
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
Yonsei University

Recruiting

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Recurrent/Metastatic Carcinosarcoma

Korea, Republic of
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Yonsei University

Completed

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

Non -Small Cell Lung Cancer

Korea, Republic of

Search clinical trials for: Neoadjuvant Nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations